Tango Therapeutics (TNGX) Capital Expenditures (2020 - 2026)
Tango Therapeutics' (TNGX) quarterly Capital Expenditures came in at -$10000.0 in Q1 2026, down 119.61% year-on-year from $51000.0 in Q1 2025, and down 112.99% quarter-over-quarter from $77000.0 in Q4 2025.
Tango Therapeutics (TNGX) Capital Expenditures (2020 - 2026) Analysis & Trends
Tango Therapeutics' Capital Expenditures history runs 7 years deep, the most recent figure standing at -$10000.0 for Q1 2026.
- On a quarterly basis, Capital Expenditures fell 119.61% year-over-year to -$10000.0 in Q1 2026; TTM through Mar 2026 was $238000.0, a 71.67% decrease from a year earlier, with the FY2025 full-year figure at $299000.0, down 60.34% from the prior year.
- Capital Expenditures retreated to -$10000.0 in Q1 2026 per TNGX's latest filing, from $77000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $6.7 million in Q3 2022 and bottomed at -$1.3 million in Q4 2023.
- The 5-year median for Capital Expenditures is $77000.0 (2025), against an average of $516058.8.
- Across the five-year window, Capital Expenditures soared 1448.6% in 2022 and tumbled 3531.25% in 2024, its largest moves.
- Year by year, Capital Expenditures stood at $1.0 million in 2022, then sank by 221.23% to -$1.3 million in 2023, then surged by 162.44% to $788000.0 in 2024, then plunged by 90.23% to $77000.0 in 2025, then sank by 112.99% to -$10000.0 in 2026.
- Per Business Quant, the three latest TNGX Capital Expenditures figures stand at -$10000.0 (Q1 2026), $77000.0 (Q4 2025), and -$84000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Tango Therapeutics | 3.94 Bn | 3.78 Bn | - | -10,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10,000.00 |
| Mar 31, 2026 | -10,000.00 |
| Dec 31, 2025 | 77,000.00 |
| Dec 31, 2025 | 77,000.00 |
| Sep 30, 2025 | -84,000.00 |
| Sep 30, 2025 | -84,000.00 |
| Jun 30, 2025 | 255,000.00 |
| Jun 30, 2025 | 255,000.00 |
| Mar 31, 2025 | 51,000.00 |
| Mar 31, 2025 | 51,000.00 |
| Dec 31, 2024 | 788,000.00 |
| Dec 31, 2024 | 788,000.00 |
| Sep 30, 2024 | -549,000.00 |
| Sep 30, 2024 | -549,000.00 |
| Jun 30, 2024 | 550,000.00 |
| Jun 30, 2024 | 550,000.00 |
| Mar 31, 2024 | -35,000.00 |
| Mar 31, 2024 | -35,000.00 |
| Dec 31, 2023 | -1.26 Mn |
| Dec 31, 2023 | -1.26 Mn |